メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
白木 良一
医学部・腎泌尿器外科学
h-index
1310
被引用数
18
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1988 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(170)
類似のプロファイル
(8)
フィンガープリント
Ryoichi Shirokiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Partial Nephrectomy
100%
Robot-Assisted Prostatectomy
65%
Cystectomy
64%
Heart Death
63%
Overall Survival
61%
Prostate Cancer
59%
Kidney Transplantation
55%
Neoplasm
46%
Transitional Cell Carcinoma
45%
Delayed Graft Function
43%
Kidney Tumour
32%
Continence
32%
Clear Cell Renal Cell Carcinoma
30%
Pembrolizumab
29%
Urinary System
28%
Retrospective Study
27%
Kidney Metastasis
27%
Brachytherapy
27%
Nivolumab
27%
Enfortumab Vedotin
27%
Bleeding
27%
Urinary Diversion
26%
Recurrence Free Survival
24%
Surgical Margin
22%
Prognostic Factor
22%
Neoadjuvant Chemotherapy
22%
Recurrent Disease
21%
Operation Duration
21%
Heart Muscle Ischemia
21%
Da Vinci Surgical System
20%
Progression Free Survival
20%
Long Term Survival
20%
Postoperative Ileus
19%
Prospective Study
18%
Neutrophil Gelatinase Associated Lipocalin
18%
Immune-Related Adverse Events
18%
Retroperitoneal Lymph Node Dissection
18%
Iodine 125
18%
Cadaver
18%
Combination Therapy
18%
Kidney Function
17%
Kidney Graft
17%
Bladder Cancer
16%
Multivariate Analysis
16%
Disease
15%
Biological Marker
15%
Geriatrics
15%
Transplantation
15%
Ischemia
15%
Urine Incontinence
14%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
60%
Heart Death
54%
Renal Cell Carcinoma
48%
Kidney Metastasis
47%
Prostate Cancer
45%
Adverse Event
38%
Delayed Graft Function
37%
Malignant Neoplasm
37%
Nivolumab
36%
Chemotherapy
29%
Castration Resistant Prostate Cancer
27%
Transitional Cell Carcinoma
27%
Disease
25%
Progression Free Survival
24%
Prostate Specific Antigen
23%
Pembrolizumab
21%
Combination Therapy
19%
Biological Marker
18%
Neutrophil Gelatinase Associated Lipocalin
18%
Cabazitaxel
18%
Ipilimumab
18%
Cadaver
18%
Abiraterone Acetate
18%
Enfortumab Vedotin
18%
Immune Checkpoint Inhibitor
18%
Neoplasm
14%
Survival Rate
14%
Protein Tyrosine Kinase Inhibitor
14%
Cisplatin
13%
Gemcitabine
12%
Androgen Receptor
11%
C Reactive Protein
11%
Sunitinib
11%
Sorafenib
11%
Immunotherapy
10%
Disease Exacerbation
10%
Liver Metastasis
10%
Vesicoureteral Reflux
10%
Docetaxel
10%
Retrospective Study
9%
Urinary Tract Infection
9%
Recurrence Risk
9%
Heat Shock Protein 27
9%
Bladder Cancer
9%
Holmium
9%
Racemase
9%
Vascular Disease
9%
Biochemical Recurrence
9%
Bacteriophage
9%
Cancer Antibody
9%
Keyphrases
Organ Recovery
18%
Robot-assisted Radical Prostatectomy
18%
Kidney Transplantation
18%
Delayed Graft Function
18%
Donation after Cardiac Death
18%
Postoperative Day
12%
Partial Nephrectomy
12%
Bicalutamide
10%
Prospective multi-institutional Study
9%
Software Analysis
9%
Renal Hilar Tumor
9%
Flow Obstruction
9%
Innovative System
9%
Outlet Obstruction
9%
Total Cell-free DNA
9%
Robotic Partial Nephrectomy
9%
Dysmetabolism
9%
Deep Ensemble
9%
Robot-assisted Radical Nephrectomy
9%
Prostate-specific Antigen Response
9%
Ensemble Machine Learning
9%
Inferior Vena Cava Thrombectomy
9%
Pentafecta Outcomes
9%
Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL)
9%
Prostate Brachytherapy
9%
Linked Seeds
9%
Renal Autotransplantation
9%
Loose Seeds
9%
Urethral Suspension
9%
Trifecta Outcomes
9%
Selective Clamping
9%
Enhanced Recovery Program
9%
Immunological Risk
9%
Robotic Surgery
9%
Trifecta
9%
Antibody Phage Library
9%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
9%
Anti-cancer Antibody
9%
Computed Tomography
9%
Premature Termination Codon
9%
Pyonephrosis
9%
Metastatic Renal Cell Carcinoma (mRCC)
9%
Islet Xenograft
9%
Upper Urinary Tract Infection
9%
Robot-assisted Laparoscopic Partial Nephrectomy
9%
RNA Kinetics
9%
Localized Kidney Cancer
9%
Surgical Systems
9%
Bladder Eversion
9%
Real-world Application
9%
